Accessibility Menu
BioLargo logo

BioLargo(OTC) BLGO

Current Price$0.11
Market Cap$36.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-84%
5 Year-36%
1 Year-39%
1 Month+1%
BioLargo last closing stock price
MetricPriceDate
Last closeUSD 0.112026-07-24
BioLargo stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.14%USD 0.112026-07-17
1 month+1.35%USD 0.112026-06-24
3 month-25.77%USD 0.152026-04-24
Year to date-38.91%USD 0.182025-12-31
1 year-38.56%USD 0.182025-07-24
3 year-37.14%USD 0.182023-07-25
5 year-35.92%USD 0.182021-07-23
Since inception-83.57%USD 0.702007-05-01

BioLargo Financials at a Glance

Market Cap

$36.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$5.61M

Net Income (TTM)

-$12.91M

EPS (TTM)

-$0.04

P/E Ratio

-2.77

Dividend

$0.00

Beta (Volatility)

0.36 (Low)

Price

$0.11

Volume

542,108

Open

$0.11

Previous Close

$0.11

Daily Range

$0.11 - $0.12

52-Week Range

$0.10 - $0.23

Estimated Earnings Date

Aug 18, 2026

BLGO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioLargo

BioLargo creates products that help clean water, air, and surfaces. Its solutions remove tough odors and dangerous chemicals for industries and consumers. The company’s technologies support safer workplaces and healthier environments.

Products and Services

  • Odor and VOC Control (ONM Environmental, 57% of Q2 2025 revenue): CupriDyne Clean reduces industrial odors and volatile organic compounds for landfills and sanitation sites; Pooph is a pet odor product sold through major retailers.
  • Water Treatment Solutions: Advanced Oxidation System and Aqueous Electrostatic Concentrator remove contaminants, including PFAS (persistent chemicals), from water for municipal and industrial clients.
  • Engineering Services (BLEST): Provides environmental engineering, compliance, and consulting, including contracts with the U.S. Air Force.
  • Battery Technology: Cellinity liquid sodium battery targets long-duration energy storage for utilities and industry.
  • Medical Products: Advanced wound care and infection control products, developed by Clyra Medical, serve healthcare providers.

Growth and Expansion

  • Partnered with Garratt-Callahan in 2023 to co-develop the AROS water reuse system.
  • Expanded Pooph pet odor product sales through Pooph Inc. to major U.S. retailers in 2023-2024.
  • Launched pilot production of Cellinity battery technology at BETI in 2024.
  • Secured new U.S. Air Force engineering contracts through BLEST in 2025.
  • Scaled up Clyra Medical’s manufacturing and distributor relationships in 2025.

What Makes BioLargo Stand Out

BioLargo operates through specialized subsidiaries, each focused on a different environmental or health challenge. Its in-house engineering team supports both product development and external projects. The company’s broad patent portfolio underpins its technology-driven approach.

Five Things You Need to Know

  • Revenue was $3 million in Q2 2025, down 44.6% from Q2 2024.
  • Pooph Inc. contributed 57% of Q2 2025 revenue.
  • Operating loss was $1.8 million in Q2 2025, an increase of 102.5% from Q2 2024.
  • Cash and cash equivalents were $3.47 million as of June 30, 2025.
  • Management expects to need more capital to fund operations in 2025.

Bottom Line

BioLargo has evolved into a multi-segment environmental technology company with a focus on innovation. Its business model relies on both proprietary products and engineering services, but faces challenges from customer concentration and ongoing losses.

AI Generated • Apr 16, 2026

Industry

Chemicals

Sector

Materials

Employees

46

CEO

Dennis P. Calvert

Website

www.biolargo.com

Headquarters

Westminster, CA 92683, US

BLGO Financials

Key Financial Metrics (TTM)

Gross Margin

42.35%

Operating Margin

-288.42%

Net Income Margin

-230.08%

Return on Equity

-244.01%

Return on Capital

-196.44%

Return on Assets

-150.73%

Earnings Yield

-36.10%

Dividend Yield

0.00%

Payout Ratio

-3.32%

Stock Overview

Market Cap

$36.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

320.88M

Volume

542.11K

Avg. Volume

469.02K

Financials (TTM)

Gross Profit

$2.38M

Operating Income

-$16.18M

EBITDA

-$15.84M

Operating Cash Flow

-$9.38M

Capital Expenditure

-$78.00K

Free Cash Flow

-$9.46M

Cash & ST Invst.

$4.12M

Total Debt

$5.66M

BioLargo Performance Analysis

BioLargo annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 5,884,000132.5%
20232023-12-31USD 12,230,000107.9%
20242024-12-31USD 17,779,00045.4%
20252025-12-31USD 7,765,000-56.3%
BioLargo sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-15.1%
Q32025-09-30-60.3%
Q42025-12-31-44.2%
Q12026-03-3181.0%
BioLargo annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.02-41.6%
20232023-12-31USD -0.01-26.9%
20242024-12-31USD -0.01-33.6%
20252025-12-31USD -0.04374.1%
BioLargo sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-2.6%
Q32025-09-30-412.8%
Q42025-12-3153.0%
Q12026-03-3123.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$1.12M

-65.9%

Gross Profit

$458.00K

-69.2%

Gross Margin

41.08%

N/A

Market Cap

$36.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$802.21K

N/A

Employees

46

N/A

Net Income

-$2.29M

-97.9%

EBITDA

-$3.09M

-72.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$4.12M

+60.8%

Total Debt

$5.66M

+85.4%

Accounts Receivable

$730.00K

-82.7%

Inventory

$292.00K

-20.9%

Long Term Debt

$3.82M

+86.5%

Short Term Debt

$1.84M

+83.0%

Return on Assets

-1.51%

N/A

Return on Invested Capital

-4.45%

N/A

Free Cash Flow

-$2.95M

-61.1%

Operating Cash Flow

-$2.92M

-59.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BIOFBlue Biofuels, Inc.
$0.11-1.74%
AUXXFA2 Gold Corp.
$0.56+4.30%
TWIRFTree Island Steel Ltd.
$1.61+6.57%
LOMLFLion One Metals Limited
$0.10-3.80%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$64.00-0.03%

Questions About BLGO

What is the current price of BioLargo?

BioLargo is trading at $0.11 per share.

What is the 52-week range for BioLargo?

Over the past 52 weeks, BioLargo has traded between $0.10 and $0.23.

How much debt does BioLargo have?

As of the most recent reporting period, BioLargo reported total debt of $5.66M.

How much cash does BioLargo have on hand?

BioLargo reported $4.12M in cash and cash equivalents in its most recent financial results.

What is BioLargo’s dividend yield?

BioLargo does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services